



25 May 2007

## Endo-microscopy featured in State of the Art Lecture at DDW

- *Profile of endo-microscopy continues to rise*
- *Presentation of excellent results from US trials*
- *Pentax active with sales and promotion*

**Washington DC, USA.** Attendees at DDW have received further presentations on endo-microscope efficacy and its emergence as a significant new imaging modality in gastro intestinal medicine.

“Endopathology is truly here.” said Dr Michael Wallace (Mayo Clinic, Jacksonville, Florida) during his State of the Art lecture on Advances in Endoscopic Diagnosis and Imaging. Summarising the excellent clinical trial results presented by doctors now experienced in endo-microscopy he said, “We now achieve histologic gold standard diagnosis. We can see neoplasia [early stage cancer]. We are capable of detailing conditions that are not cancer”.

The excellent trial results being obtained by doctors using the Pentax ISC 1000 endo-microscope included two new clinical trials performed at Johns Hopkins Hospital (Baltimore, USA). These two trials set out to demonstrate how long it takes doctors to benefit from using Pentax/Optiscan endo-microscopes, and how consistently and accurately different doctors can interpret endo-microscope images.

The first, a presentation by Dr Mimi Canto et al, reported the impact on the efficiency and accuracy of diagnosis made by gastroenterologists at the time of endoscopy using the Pentax ISC 1000 endo-microscope. Over two patient groups, endo-microscopy on average indicated the need for 9 less biopsies than standard methods, and changed the endoscopic diagnosis in 36% of patients with no known disease. Importantly, careful measurements of procedure duration showed that endo-microscopy did not require additional time. The investigators concluded “CLE (confocal laser endoscopy) diagnosis of Barrett’s esophagus and associated neoplasia is possible with high accuracy and without prolonging procedure time” and “in vivo microscopy can immediately change the macroscopic diagnosis”.

The second presentation, by Dr Kerry Dunbar et al, reported results of the first US based learning curve and inter-observer agreement study. The results showed a high level of inter-observer agreement amongst gastroenterologists (kappa statistic = 0.68). The study concluded “In vivo histology provided by confocal laser endo-microscopy can be interpreted by gastroenterologists, with similar results compared to pathologists, even after limited experience with this new endoscopic imaging technique”.

“These are great results supporting the development of the US market for endo-microscopy.” said Mr Peter Delaney, Optiscan’s Director of Technology, “They show that use of the Pentax ISC 1000 endo-microscope is easily learned, saves procedure time, and improves the efficiency of endoscopic procedures within the time pressured US healthcare environment.”

Elsewhere, active sales and promotion for the Pentax ISC 1000 continued at DDW. The instrument featured on Pentax’s extensive exhibit where many attending doctors had the opportunity to use the instrument and to review endo-microscope images of normal and abnormal tissue.



## **About DDW**

Digestive Diseases Week is the largest and most prestigious annual congress in gastro intestinal medicine. DDW's sponsoring and organising societies include the American Gastroenterological Association (AGA) and the American Society of Gastrointestinal Endoscopy (ASGE).

DDW is convened annually in May with a different US city hosting the event each year. DDW 2007 is being held in Washington DC from Sunday 19 May to Thursday 24 May.

All major advances in the field of gastro intestinal medicine are presented at DDW. The organising societies provide peer review and acceptance of abstracts for all presentations made during the congress.

Companies selling instruments, pharmaceuticals and other equipment used in gastro intestinal medicine exhibit their products in an extensive exhibition hall. Optiscan's partner Pentax is a major exhibitor, and the Pentax ISC-1000 flexible endo-microscope is featured in active demonstrations on their exhibit.

## **About Optiscan**

Optiscan is a global leader in microscopic imaging technologies for medical markets.

Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Pentax is the second largest producer of flexible endoscopes in the US\$1.2Bn pa global flexible endoscope market. Pentax has been licensed by Optiscan to use its patented miniaturised microscope technology. Pentax released the world's first fully functional flexible endo-microscope, ISC-1000, for sale in March 2006. Optiscan manufactures and sells to Pentax the high value key operating components of the miniaturised endo-microscope system.

Further information:

Matthew Barnett, CEO  
Tel (613) 9538 3347  
matthewb@optiscan.com

Bruce Andrew, CFO  
Tel (613) 9538 3398  
brucea@optiscan.com